MM&M1d
Rx Rundown: Sanofi, Novartis, Roche and more
The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...
Daily1d
FDA Approves First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
The U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived ...
kffhealthnews1d
FDA Approves ARC-EX Device For Non-Invasive Spinal Cord Stimulation
Meanwhile, synthetic gel aids in recovery after spinal surgery; Pittsburgh researchers create helper robots for people with ALS; a study finds nerve stimulation is effective against ...
Frontiers2d
Microbiota-Immune Interactions: A New Frontier in Cancer Treatment Optimization
The field of microbiome research, particularly its interaction with immunotherapy, is rapidly evolving and holds significant promise for enhancing cancer ...
Hot Stocks: Exosome Breakthrough, Gas Pipeline Deals and More
A round up of some stocks capturing attention this week, featuring INOVIQ, Tamboran Resources, Omni Bridgeway, Clarity Pharmaceuticals and Mesoblast.
Why the Mesoblast share price is diving 18% after an FDA win
The Mesoblast Ltd (ASX: MSB) share price is taking a dive today. Here’s why the biotech stock is under pressure after ...
Cell Source Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American Society of Hematology Annual Meeting
Dr. Reisner is chair of the scientific advisory board for Cell Source and has equity in the company. These financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee ...
Investor's Business Daily on MSN2d
Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval
Mesoblast snagged Food and Drug Administration approval for the first-ever treatment for children with a form of graft vs.
Mesoblast awarded FDA approval for Ryoncil
Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration (FDA) for Ryoncil (remestemcel-L), making ...
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...
Monthly Prescribing Reference2d
Mesenchymal Stromal Cell Therapy Ryoncil Gets FDA Approval
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...